36 results about "Inhalation Solution" patented technology

The application discloses a modified bromhexine hydrochloride inhalation solution with enhanced stability and a preparation method thereof, and belongs to the technical field of medical preparations. The inhalation solution is mainly prepared from a targeting impurity control modified bromhexine hydrochloride inclusion compound, a special composite buffer mother liquor for inhibiting impurity B, inhalation grade sodium chloride, pharmaceutical grade sodium hydroxide and water for injection, and the pH value of the finished product is 4.5-5.5. The application constructs a three-stage progressive modification system, covalently grafts a mercapto-activated L-cysteine derivative onto hydroxypropyl-gamma-cyclodextrin to prepare a functional carrier, and realizes molecular-level isolation of bromhexine hydrochloride through host-guest inclusion, thereby blocking the generation of impurity B of bromhexine hydrochloride from the whole path, and solving the core pain points of easy impurity exceeding, short effective period and airway irritation of the existing product. The application can realize long-acting stable storage for 36 months, is suitable for the existing industrial production line, and has high clinical application and industrialization values.

The invention relates to a detection method of a revivacin inhalation solution, and belongs to the technical field of medicine detection. According to the detection method provided by the invention, a revivin inhalation solution sample is analyzed by adopting high performance liquid chromatography to obtain the content of impurities in the revivin inhalation solution; the high performance liquid chromatography uses a phosphate buffer as a mobile phase A and acetonitrile as a mobile phase B, and the elution conditions are as follows: 0-5 min, the volume ratio of the mobile phase A to the mobile phase B is gradually changed from 95: 5 to 80: 20; the volume ratio of the mobile phase A to the mobile phase B is gradually changed from 80: 20 to 20: 80 in 5-30 min; the volume ratio of the mobile phase A to the mobile phase B is 95: 5. The method provided by the invention can realize accurate detection of five different impurities in the revienacin inhalation solution, and is beneficial to actual production quality control and improvement of drug safety.

The application relates to the field of traditional Chinese medicine quality control, and particularly discloses a quality control method for Shuanghuanglian inhalation solution. The method can simultaneously determine the fingerprint spectrum and ingredient content of the Shuanghuanglian inhalation solution. The fingerprint spectrum detection method disclosed by the application adopts UPLC determination, has 17 characteristic peaks, and attributes 8 characteristic peaks. The contents of neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, isochlorogenic acid B, isochlorogenic acid A, isochlorogenic acid C and forsythoside are simultaneously determined. Compared with the prior art, the method for determining the fingerprint spectrum and content of the Shuanghuanglian inhalation solution is improved, and the quality of the Shuanghuanglian inhalation solution can be comprehensively monitored conveniently, quickly and accurately.

The invention relates to an application of genipin-1-beta-D gentiobioside in preparation of a medicine for treating chronic obstructive pulmonary disease. The genipin-1-beta-D gentiobioside is prepared into an aerosol inhalation solution, and the aerosol inhalation administration mode is adopted, so that the lung function in the chronic obstructive pulmonary disease can be improved, the content of inflammatory factors in lung tissues can be reduced, and the lung tissue injury can be relieved.

The invention belongs to the technical field of biological medicines, and particularly relates to a honeysuckle total extract inhalation solution as well as a preparation method and application thereof. According to the invention, the honeysuckle total extract with poor water solubility, phospholipid and chitosan are innovatively and directionally assembled into the chitosan-phospholipid nanoparticles with uniform structure, and the nanoparticles are prepared by adopting a microfluidic technology. The strategy significantly improves the water solubility and stability of the honeysuckle total extract, and successfully prepares an inhalation solution suitable for pulmonary administration based on the nanoparticle dispersion system. The obtained preparation has the characteristics of high physical stability and good bioavailability potential. The honeysuckle total extract inhalation solution provided by the invention can effectively relieve the pathological process of the pyotoxic pneumonia through multiple mechanisms of remarkably inhibiting lung inflammatory response, relieving pulmonary edema, protecting the structural integrity of pulmonary alveoli and the like. Especially, a high-dose group shows a curative effect superior to that of a positive control drug, and a good dose-effect relationship is combined, so that the preparation has remarkable development potential and clinical transformation prospect in treatment of the septic pneumonia.

The present application provides a kind of nintedanib solution for inhalation and preparation method and application, the inhalation solution includes active substance, solvent and auxiliary material, the single dose specification of the inhalation solution is 1-5ml, and the active substance in single dose specification is 2.41-12.04mg / ml nintedanib ethanesulfonic acid;The solvent is sterile injection solution water;The auxiliary material includes isotonicity regulator and pH regulator and can also include antioxidant;The addition amount of the isotonicity regulator is to make the inhalation solution have the weight molal osmotic concentration of 240-400mOsmol / kg;The addition of the pH regulator is to make the pH value of the inhalation solution preparation 3.0-4.0.The inhalation nintedanib solution of the present application can provide a kind of nintedanib for inhalation with convenient, safe and effective, and good stability of drug dosage form and drug delivery system in combination with liquid atomization device.

The application discloses a pirfenidone nanosuspension inhalation solution for treating interstitial pneumonia and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The pirfenidone nanosuspension inhalation solution is composed of the following components in 1000ml: 8-12g of pirfenidone hydrochloride, 4-6g of polyethylene glycol-poly-L-histidine block copolymer, 45-55g of mannitol, 0.4-0.6g of antioxidant, 0.05mol / L of citric acid-sodium citrate buffer, and water for injection, wherein the amount of the citric acid-sodium citrate buffer is appropriate, and the water for injection is added to 1000ml. The application adopts a pulmonary targeted inhalation administration path of non-gastrointestinal absorption, so that the drug directly acts on the lung interstitial lesion part by bypassing the intestinal absorption link.

The invention belongs to the technical field of analysis and detection, and relates to a method for detecting nitrosamine impurities in a terbutaline sulfate aerosol inhalation solution. The method comprises the following steps: diluting a terbutaline sulfate aerosol inhalation solution to obtain a test solution; detecting the test solution by adopting an ultra-high performance liquid chromatography-tandem mass spectrometry method; wherein the chromatographic conditions are as follows: a filling agent of a chromatographic column is octadecylsilane chemically bonded silica; the mobile phase A is an ammonium acetate aqueous solution; the mobile phase B is acetonitrile; the nitrosamine impurity is N-nitroso-terbutaline, and the nitrosamine impurity is N-nitroso-terbutaline. The method for detecting the N-nitroso-terbutaline impurities in the terbutaline sulfate aerosol inhalation solution by adopting the ultra-high performance liquid chromatography-tandem mass spectrometry technology is proposed for the first time, the method is high in selectivity, the quantitation limit is as low as 1.5% of the limit, the detection limit is as low as 0.5% of the limit, detection can be completed only in 10 minutes, and the method is suitable for large-scale popularization and application. Powerful guarantee is provided for effectively controlling the medicine quality and guaranteeing the medicine safety.

The application discloses an inhaled solution medicine production line wastewater environment-friendly treatment device, which comprises a treatment tank, a storage tank for storing high-efficiency activated carbon powder, an agitating device for agitating liquid in the treatment tank and a stirring plate rotationally connected with the agitating device, and further comprises a material scattering device for scattering the high-efficiency activated carbon powder into the liquid for catalysis when the liquid enters the treatment tank. When the wastewater is added and enters a catalytic oxidation stage, hydrogen peroxide needs to be separately injected. If the linkage is not cut off, the liquid flow at the water inlet will trigger the blocking plate again, so that the excessive high-efficiency activated carbon enters the treatment tank. The sliding block drives the connecting rod to be displaced, so that the connecting rod is separated from the blocking plate, and mechanical limiting is realized through the key, so that the solid-liquid ratio in the tank is kept constant, and the influence of the excessive high-efficiency activated carbon on the subsequent catalysis is avoided.

The present invention belongs to the field of drug therapy, and specifically relates to the use of methyl parahydroxybenzoate and its sodium salt in the preparation of drugs for treating viral infectious diseases. The present invention discloses the use of methyl parahydroxybenzoate, its sodium salt and its inhalation preparation in the treatment of coronavirus infectious diseases. By verifying the new use of methyl parahydroxybenzoate and its sodium salt inhalation solution in a mouse test infected with human coronavirus HCoV-229E, the technical solution has novelty, and an efficacy test of meta-cresol inhalation solution in treating pneumonia caused by HCoV-229E virus infection was conducted. The results showed that methyl parahydroxybenzoate and its sodium salt inhalation solution showed good efficacy in the lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, and could significantly reduce the mouse lung index.

The invention relates to the technical field of substance impurity detection methods, in particular to a procaterol hydrochloride inhalation solution related substance detection method which adopts high performance liquid chromatography for detection, and chromatographic conditions are as follows: mobile phases include a mobile phase A and a mobile phase B; the mobile phase A is a phosphate buffer solution, and the mobile phase B is methanol. The method can effectively detect the related substances in the procaterol hydrochloride inhalation solution, has the advantages of strong specificity, high sensitivity and comprehensive impurity control, and can better control the quality of a preparation.

The invention relates to a revienacin inhalation solution and a preparation method thereof. The revienacin inhalation solution comprises revienacin, a stabilizing agent, a buffering agent and water for injection, wherein the stabilizer is disodium edetate and propylene glycol, and the mass volume ratio of the disodium edetate to the propylene glycol is (0.05-0.1) g: (50-300) ml. The revivin inhalation solution can effectively delay degradation of revivin under the high-temperature condition, the long-term stability of a preparation under the high-temperature condition is guaranteed, the preparation prescription and the preparation process are simple and easy to operate, and the revivin inhalation solution is suitable for large-scale industrial production.

1. Name of the designed product: package box (formoterol fumarate). 2. Use of the designed product: the designed product is used for packing formoterol fumarate inhalation solution. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo best indicating the design points: perspective view.

The invention provides an inhalation solution for bronchial constriction maintenance treatment of a chronic obstructive pulmonary disease patient and a preparation method of the inhalation solution, and relates to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: adding 50-95% of water for injection into a liquid preparation tank, cooling the water for injection to 50 DEG C, starting stirring, synchronously and sequentially adding sodium chloride, citric acid and sodium citrate according to the prescription dosage, stirring to dissolve the sodium chloride, the citric acid and the sodium citrate, continuously cooling to 40 DEG C, adding formoterol fumarate according to the prescription dosage, stirring to dissolve for 60 minutes, fixing the volume, and stirring again for 10 minutes for later use. According to the preparation method of the formoterol fumarate inhalation solution provided by the invention, process parameters are accurately controlled, so that the sterility guarantee level of the formoterol fumarate inhalation solution can be improved, the increase of the impurity content can be effectively controlled, and good stability of the formoterol fumarate inhalation solution is ensured.

SOLUTION: Provided herein is a liquid formulation comprising recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) for inhalation by nebulization.SELECTED DRAWING: None

There is provided a budesonide nebulization inhalation solution composition and its application. The composition, which is a budesonide nebulization inhalation solution composed of budesonide, a pH adjuster, and water, has, as the particle size of the spray droplets, D 90 The particle size is 7.0 to 10.0 μm, D 50 The particle size is 2.8 to 4.5 μm, D 10 The particle size is 0.5 to 1.5 μm, and the deposition percentage of particles with an aerodynamic diameter of 1.4 to 5.4 μm in the budesonide inhalation solution is 50% or more. Further provided is a medicinal assembly for use in combination with a nebulization inhalation solution, comprising an inhalation composition, a nebulizer with specific parameters, and a nebulizer cup. The budesonide nebulization inhalation solution composition and its medicinal assembly have the advantages of a small effective amount, rapid onset of effect, and high drug delivery efficiency, and are particularly effective in the treatment of tracheal and main bronchial diseases.

A fudosteine nebulization inhalation solution composition and use thereof. The fudosteine nebulization inhalation solution consists of fudosteine, a pH-adjusting agent and water. The droplet particle size of the composition is as follows: the D90 particle size is 7.0-10.0 µm, the D50 particle size is 2.8-4.5 µm, and the D10 particle size is 0.5-1.5 µm; and the percent deposition of the particles with the aerodynamic particle size of 1.4-5.4 µm in the fudosteine inhalation solution is not less than 50%. In addition, further provided is a drug assembly for use in conjunction with the nebulization inhalation solution, comprising the inhalation composition, and a nebulizer and a nebulizing cup with specific parameters. The fudosteine nebulization inhalation solution composition and the assembly thereof have the advantages of a small effective dose, acting fast, high drug delivery efficiency, and the like, and are particularly effective in treating tracheal and main bronchial diseases.

The invention relates to a medicinal preparation for treating pulmonary arterial hypertension as well as a preparation method and application of the medicinal preparation. Every 1000mL of liquid preparation comprises 0.3-18mg of beraprost or pharmaceutically acceptable salt thereof, 0-15g of an osmotic pressure regulator, 0.05-15g of a buffering agent, 0-0.5 g of a metal chelating agent, 0-15g of a pH regulator and water for injection. The beraprost inhalation solution is more stable in physicochemical property, higher in bioavailability, higher in safety, smaller in toxicity, smaller in irritation and higher in patient use compliance, and meets clinical medication requirements.

This invention relates to a polymyxin inhalation liquid formulation and its preparation method, comprising 0.1-5% (w / v) polymyxin B sulfate, 0.05-1% (w / v) stabilizer, 0.1-0.9% (w / v) osmolarity regulator, pH adjuster, and solvent; the pH of the liquid formulation is 3.0-6.0; the solvent is selected from purified water and water for injection; the polymyxin inhalation solution provided by this invention has a simple composition, a pH of 3.0-6.0, and is osmotonic, which can reduce bronchospasm and cough caused by polymyxin inhalation solution. Safety evaluation has verified that it has good safety, providing a new option for clinical application.

The invention provides a rafenasin inhalation solution composition and a preparation method thereof. The rafenasin inhalation solution composition is prepared from the following components: rafenasin, a buffer pair, sodium chloride, hydrochloric acid or sodium hydroxide and water, wherein the acidic compound of the buffer pair is one or more of phosphoric acid, acetic acid, boric acid, gallic acid, cysteine, glycolic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, tartaric acid and benzoic acid. In the technical scheme, the refenasin inhalation solution composition uses a buffer pair except citric acid, so that the stability of the solution is improved, the composition can tolerate excessive killing and sterilization, the safety is higher, and the production cost is lower.

The invention discloses a medicine assembly containing an etimicin sulfate solution and application of the medicine assembly. The medicine assembly comprises (a) the etimicin sulfate solution; the vibrating screen atomizer is used in cooperation with the etimicin sulfate solution; 1500-2200 micropores are formed in the central area of an atomizing sheet of the vibrating screen atomizer; the diameter of each micropore is 2.2 microns to 3.8 microns; wherein the vibration frequency of the vibrating screen atomizer is 90-120KHZ; the sections of the micropores in the vibrating screen atomizer are distributed in a step shape, and the taper is 18 degrees. The nebulizer is matched with the etimicin sulfate inhalation solution for use, so that the administration efficiency of the etimicin sulfate inhalation solution is improved, and the medicine can safely reach an effective treatment concentration in the lung. In addition, the form can improve the amount of delivered medicine, can deposit a large amount of medicine in terminal bronchus and pulmonary alveoli, increases the proportion of fine fog drops reaching the lung, shortens the atomization time, and reduces the volume of medicine liquid residues.

The present application provides a kind of nintedanib solution for inhalation and preparation method and application, the inhalation solution includes active substance, solvent and auxiliary material, the single dose specification of the inhalation solution is 1-5ml, and the active substance in single dose specification is 2.41-12.04mg / ml nintedanib ethanesulfonic acid;The solvent is sterile injection solution water;The auxiliary material includes isotonicity regulator and pH regulator and can also include antioxidant;The addition amount of the isotonicity regulator is to make the inhalation solution have the weight molal osmotic concentration of 240-400mOsmol / kg;The addition of the pH regulator is to make the pH value of the inhalation solution preparation 3.0-4.0.The inhalation nintedanib solution of the present application can provide a kind of nintedanib for inhalation with convenient, safe and effective, and good stability of drug dosage form and drug delivery system in combination with liquid atomization device.

The invention relates to the technical field of pharmaceutical preparations, and discloses a formoterol fumarate inhalation solution and a preparation method thereof. The formoterol fumarate inhalation solution provided by the invention is prepared from the following components in mass concentration: 0.05 percent to 0.2 percent of sodium hydroxide, 0.6 percent to 1.0 percent of tartaric acid, 0.1 percent to 0.3 percent of aminocaproic acid, 0.001 percent to 0.1 percent of polysorbate 20, 0.0009 percent to 0.0011 percent of formoterol fumarate, 0.7 percent to 0.9 percent of sodium chloride and the balance of water for injection. By adjusting the pH value of the solution, adding the polysorbate 20 and the aminocaproic acid, controlling the raw materials and the dissolving temperature thereof, filling nitrogen in the dissolving process and the filling process, and combining filtration and sterilization, the invention provides a method for improving the stability of the product under the condition of controlling the impurity level of the product. And the preparation method can be used for industrially producing the formoterol fumarate inhalation solution.

The invention provides a refenasin inhalation solution and a preparation method thereof. The refenasin inhalation solution comprises an active component refenasin, a pH buffer agent, an osmotic pressure regulator and a stabilizer. The stability of the rafenasin inhalation solution under ultrasonic atomization can be remarkably improved, the storage stability is good, and the effect of the better lung deposition rate is achieved.

The present invention belongs to the field of drug therapy, and specifically relates to the use of ethyl parahydroxybenzoate in the preparation of drugs for preventing or treating viral infectious diseases. The present invention discloses the use of ethyl parahydroxybenzoate and its inhalation preparation in the treatment of coronavirus infectious diseases. By verifying the new use of ethyl parahydroxybenzoate inhalation solution in a mouse test infected with human coronavirus HCoV-229E, the technical solution has novelty, and an efficacy test of meta-cresol inhalation solution in the treatment of pneumonia caused by HCoV-229E virus infection was conducted. The results showed that ethyl parahydroxybenzoate inhalation solution showed good efficacy in the lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, and could significantly reduce the lung index of mice.

The present invention provides a levosalbutamol hydrochloride nebulized inhalation solution composition and a preparation method thereof, belonging to the technical field of pharmaceutical preparations. The composition comprises levosalbutamol hydrochloride, a costabilizer, an osmotic pressure regulator, a pH regulator, and a solvent. Edetate disodium, gentisic acid, and sodium diacetate are used as costabilizers. The costabilizers enhance the stability of the composition and extend its storage time. Furthermore, the composition simplifies the preparation process without nitrogen filling protection, reduces the requirements for production equipment, is simple and easy to operate, and has low production costs.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to an epimedin C solution for inhalation as well as a preparation method and application thereof. The preparation provided by the invention can improve the bioavailability of the epimedin C, enhance lung targeting, reduce systemic toxicity and improve the stability of the epimedin C, can effectively treat lung inflammation, and has a good application prospect.

1. Name of the product of this design: Medicine box (Procaterol hydrochloride inhalation solution). 2. Purpose of this design product: used for outer packaging of medicines. 3. The key design points of this design product lie in the shape, pattern and their combination. 4. The picture or photo that best illustrates the key points of the design: main view.

The invention relates to the field of analytical chemistry, and particularly discloses a method for separating impurities in a rafenasin inhalation solution by high performance liquid chromatography, which adopts octadecylsilane chemically bonded silica as a filler, a dibasic hydrogen phosphate solution as a mobile phase A and methanol-acetonitrile as a mobile phase B to carry out gradient elution, according to the method, all known impurities and unknown impurities in a rafenasin inhalation solution can be effectively separated, five impurities are effectively separated in one chromatography, the separation degree between a main peak and an impurity IX reaches 2.7, the separation degrees of other impurities are all larger than 1.5, the specificity is good, interference of a blank solvent and other unknown impurities is avoided, the separation efficiency is high, the anti-interference capability is high, and the method is suitable for industrial production. The analysis speed is high, and the detection accuracy is high, so that the quality of the rafenasin inhaled solution is effectively controlled.

The invention relates to the technical field of discharge leak detection, and particularly discloses a discharge leak detection device and method after procaterol hydrochloride inhalation solution packaging, and the method comprises the steps: carrying out the real-time collection of the surface image data of each electrode of a procaterol hydrochloride inhalation solution packaging bottle in the leak detection process through an image collection module; the roughness characteristics in the surface image data of each electrode are cleaned and corrected through the data cleaning module, so that the accuracy of the roughness characteristic data can be improved, reliable data support is provided for subsequent analysis of real-time pollution conditions of different electrodes, and the analysis accuracy of the real-time pollution conditions of different electrodes is improved. And then actual output current values of different electrodes are calculated based on pollution conditions of different electrodes, so that dynamic adjustment of a current monitoring threshold can be realized, and the accuracy of a comparison result of the current values near different electrodes and the current monitoring threshold in a leak detection process is improved. Further, the accuracy of the analysis result of the sealing performance of the procaterol hydrochloride inhalation solution packaging bottle is improved.